Stockscreener 앱 받기
54.59
0.87%
-0.48
Biomarin Pharmaceutical Inc 주식(BMRN)의 최신 뉴스
Aug Volume: Is BioMarin Pharmaceutical Inc stock risky to hold nowDividend Hike & Daily Profit Maximizing Trade Tips - baoquankhu1.vn
Korea’s Ildong promotes Chae Joon Lee to co-CEO - BioCentury
FOLD Rises 136% in 6 Months: Should You Buy, Sell or Hold the Stock? - Finviz
Why BioMarin Pharmaceutical (BMRN) is a Top Momentum Stock for the Long-Term - Yahoo Finance
BioMarin’s PALace Study: Long-Term Safety Check on Palynziq and What It Means for Investors - TipRanks
Zacks.com featured highlights include Universal Health Services, PNC Financial Services, Global Payments and BioMarin Pharmaceutical - The Globe and Mail
11 potential new genetic-disease medicines as BioMarin maps $4B push - Stock Titan
BioMarin drops development of liver, lung disease asset - MSN
Humana Partners With Atlas to Enhance Cancer Care for Seniors - TradingView — Track All Markets
4 Value Stocks to Buy As Wall Street Weighs Trump Policies - The Globe and Mail
BioMarin names Arpit Davé as Chief Digital and Information Officer - The American Bazaar
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock - sharewise.com
BMRN or TARS: Which Is the Better Value Stock Right Now? - Yahoo Finance
Is BioMarin Pharmaceutical (BMRN) a Great Value Stock Right Now? - Yahoo Finance
BioMarin Pharmaceutical touts $3.2B 2025 revenue, Voxzogo surge and Amicus deal at JPM Conference - MarketBeat
BioMarin Pharmaceutical Reports Preliminary 2025 Revenue, Details Asset Write-Down - marketscreener.com
BioMarin appoints Arpit Davé as chief digital and information officer By Investing.com - Investing.com Nigeria
Lobbying Update: $30,000 of BIOMARIN PHARMACEUTICAL INC. lobbying was just disclosed - Quiver Quantitative
BioMarin appoints Arpit Davé as chief digital and information officer - Investing.com
Biomarin Pharmaceutical Inc estimates $3.2 billion in total revenues for FYSEC filing - marketscreener.com
BioMarin Pharmaceutical Names Arpit Dave Chief Digital and Information Officer - marketscreener.com
BMRN: Strong growth, pipeline progress, and Amicus integration position for sustained double-digit CAGR - TradingView — Track All Markets
BioMarin Appoints Arpit Davé Chief Digital and Information Officer - PR Newswire
Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term - Yahoo Finance
Why (BMRN) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Veeva and BioMarin form strategic partnership to accelerate therapies By Investing.com - Investing.com Nigeria
How BioMarin Pharmaceutical Inc. (BM8) stock compares with tech leaders2025 EndofYear Setup & AI Powered Buy/Sell Recommendations - ulpravda.ru
Veeva and BioMarin Form Long-Term Strategic Partnership - Sahm
What RSI levels show for BioMarin Pharmaceutical Inc. (BM8) stockPortfolio Performance Summary & High Accuracy Investment Entry Signals - ulpravda.ru
BioMarin to Present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, at 11:15 am PT / 2:15 pm ET, in San Francisco, CA - Chartmill
Will BioMarin Pharmaceutical Inc. stock outperform Nasdaq indexIPO Watch & Stepwise Entry/Exit Trade Alerts - ulpravda.ru
What catalysts could drive BioMarin Pharmaceutical Inc. stock higher2025 EndofYear Setup & Fast Exit and Entry Trade Guides - ulpravda.ru
Is BioMarin Pharmaceutical Inc. (BM8) stock a buy during volatile marketsPortfolio Risk Report & Free Community Consensus Stock Picks - ulpravda.ru
California biotech BioMarin will pay $4.8 billion for Amicus Therapeutics, a rare-disease company with a presence in Philadelphia - MSN
Veeva, BioMarin Enter Long-Term Strategic Partnership - Contract Pharma
Veeva Systems Expands Long-Term Partnership With BioMarin Pharmaceutical - Nasdaq
Veeva and BioMarin form strategic partnership to accelerate therapies - Investing.com
Veeva-BioMarin tech partnership to help speed new medicines to patients - Stock Titan
BioMarin fends off Kuvan generics competition again - The Pharma Letter
Robeco Institutional Asset Management B.V. Boosts Stock Position in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Published on: 2026-01-08 12:48:27 - Улправда
HC Wainwright: BioMarin’s (BMRN) Amicus acquisition stabilizes cash flow while Voxzogo remains near-term driver - MSN
10 Magnificent Stocks That Can Make You Richer in 2026 - The Motley Fool
Taking a Fresh Look at BioMarin Pharmaceutical’s (BMRN) Valuation After Its Recent Share Price Rebound - Sahm
How Investors Are Reacting To BioMarin (BMRN) Halting BMN349 And Refocusing Its Rare Disease Pipeline - Yahoo Finance
19,329 Shares in BioMarin Pharmaceutical Inc. $BMRN Acquired by Financiere des Professionnels Fonds d investissement inc. - MarketBeat
Technical Analysis: What RSI levels show for BioMarin Pharmaceutical Inc BM8 stock2025 Market Trends & Free Expert Verified Stock Movement Alerts - moha.gov.vn
Investor Mood: How BioMarin Pharmaceutical Inc stock performs in weak economyJuly 2025 Pullbacks & Safe Entry Trade Reports - moha.gov.vn
Blue Trust Inc. Sells 17,973 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BioMarin’s $4.8 Billion Amicus Acquisition: A Strategic Pivot to Rare Disease Dominance - FinancialContent
These Bay Area drugmakers are hurtling toward key FDA approval decisions in 2026 - The Business Journals
VIRGINIA RETIREMENT SYSTEMS ET Al Reduces Stock Position in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
H.C. Wainwright: BioMarin’s (BMRN) Amicus Acquisition Stabilizes Cash Flow While Voxzogo Remains Near-Term Driver - Insider Monkey
H.C. Wainwright: BioMarin's (BMRN) Amicus Acquisition Stabilizes Cash Flow While Voxzogo Remains Near-Term Driver - Finviz
12 Best NASDAQ Stocks to Buy in 2026 - Insider Monkey
BioMarin Acquiring Amicus — Both Great Companies, Only One Worth Buying Now (NASDAQ:BMRN) - Seeking Alpha
Is BioMarin Pharmaceutical Inc. (BMRN) the Ridiculously Cheap Stock to Buy Now? - Finviz
4.73%
0.92%
자본화:
|
볼륨(24시간):